Prostate Specific Antigen ELISA Kit

Catalog No. ABIN577067

This Colorimetric ELISA kit is designed for the quantitative measurement of Human Prostate Specific Antigen. There is 1 publication available.

Quick Overview for Prostate Specific Antigen ELISA Kit (ABIN577067)

Target: Prostate Specific Antigen (PSA)

Reactivity: Human

Detection Method: Colorimetric

Method Type: Sandwich ELISA

Application: ELISA

Product Details Prostate Specific Antigen ELISA Kit

Purpose: This PSA enzyme linked immunosorbent assay (ELISA) applies a technique called a quantitative sandwich immunoassay. The microtiter plate provided in this kit has been pre-coated with a monoclonal antibody specific for PSA. Standards or samples are then added to the microtiter plate wells and PSA, if present, will bind to the antibody pre-coated on the wells. In order to quantify the amount of PSA present in the sample, a standardized preparation of horseradish peroxidase (HRP)-conjugated monoclonal antibody, specific for PSA are added to each well to

Analytical Method: Quantitative

Sensitivity: Estimated to be 1 ng/mL PSA antigen in human serum.

Components: Standards: 1 set/2 vials

Application Details

Plate: Pre-coated

Restrictions: For Research Use only

Handling

Preservative: Without preservative

References for Prostate Specific Antigen ELISA Kit (ABIN577067)

Petiwala, Berhe, Li, Puthenveetil, Rahman, Nonn, Johnson: "Rosemary (Rosmarinus officinalis) extract modulates CHOP/GADD153 to promote androgen receptor degradation and decreases xenograft tumor growth." in: PLoS ONE, Vol. 9, Issue 3, pp. e89772, (2014) (PubMed).

Target Details for Prostate Specific Antigen

Target: Prostate Specific Antigen (PSA)

Background: Hepatitis resulting from infection with viruses other than Hepatitis A Virus (HAV) and Hepatitis B (HBV) virus was previously referred to as non-A, non-B hepatitis. The first characterised non-A, non-B hepatitis agent was that responsible for parentally transmitted non-A, non-B hepatitis, or what is now called Hepatitis C Virus. This was followed by the cloning of a portion of the fecal-orally-transmitted agent, the Hepatitis E Virus (HEV). Hepatitis E Virus has been referred to as enterically transmitted non-A, non-B hepatitis. Epidemics of enterically transmitted Hepatitis E Virus have been recognised worldwide but occur principally in developing countries. They have been reported in Southeast Asia, central Asia, Africa, Mexico, and Central America. In these areas, contaminated water has been implicated as the principal vehicle of virus transmission. Although HEV and HAV are transmitted in a similar manner, there are major differences in the clinical, pathological, and epidemiological courses of these two viruses. In particular, the mortality rate for HEV infection is 1 to 2%, or approximately 1-fold greater than that seen for HAV. Infection with HEV is particularly fatal for pregnant women, for whom the mortality rate can be as high as 1 to 2%

Pathways: Complement System